Digestive Disease Week 2016 in San Diego Part II

Digestive Disease Week 2016 in San Diego Part IIDigestive Disease Week 2016

Digestive Disease Week 2016 (DDW2016, #DDW16) took place in San Diego last month. According to its website, it is the world’s largest gathering of doctors and researchers in the fields of gastroenterology, hepatology, endoscopy, and geastrointestinal surgery. This blog post is a collection of just some of the research about hep C treatments discussed at the Digestive Disease Week 2016.

Research Presented at the Digestive Disease Week 2016 about Hepatitis C Treatment Topics

  • 100% Svr4 and Favorable Safety of Abt-493 + Abt-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (Surveyor-I) by Edward Gane, et al.

Summary: The combination of the antivirals ABT-493 and ABT-530 was well tolerated and resulted in 100% SVR/”cure rate” when tested 4 weeks after treatment in non-cirrhotic patients with a genotype 4, 5, or 6 hep C infection.

  • Age No Bar With New Anti-HCV Directly Acting Anti-Viral Agents: Real World Experience at a Single Tertiary Care Center in Rural Pennsylvania by Amir N. Rezk, et al.

Summary: This study looked at hep C treatment results of patients 70 to 90 years of age, with a mean age of 75 years old. The study concluded that age doesn’t affect success rates of DAA treatments.

  • Clinical Benefits of Successful Treatment in HCV Infected Patients With Decompensated Cirrhosis Treated With Sofosbuvir/Velpatasvir (Sof/VEL) by Robert S Brown, et al.

Summary: Patients with decompensated cirrhosis achieved high SVR12 with sofosbuvir/velpatasvir. These patients “…had a higher probability of clinical improvement if they had a higher MELD score, lower (<30) BMI or the absence of ascites and encephalopathy at the time of enrollment.” (Robert S Brown, et al.)

  • Comparative Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in 6,961 Genotype 1 Patients Treated in Routine Medical Practice by Lisa I Backus, et al.

Summary: A large real-world study looking at patients with hep C genotype 1 infections that had been treated. It concluded that SVR rates were similar to those found in clinical trials.

  • Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis by Christophe Hezode, et al.

Summary: Daclatasvir + sofosbuvir + ribavirin for 12 or 16 weeks resulted with SVR12 100% in patients with hep C genotype 3 infections and advanced fibrosis and  SVR12 87% in patients with liver cirrhosis who  failed previous interferon- or sofosbuvir-based therapies.

  • Genotype Subtype and Gender Influence SVR12 Rate With Directing Antiviral Therapy in Well Compensated Hepatitis C Related Cirrhosis by Amitkumar Patel, et al.

Summary: The study tried to evaluate cure rates in cirrhotic patients undergoing DAA therapy and identify predictors of response/non response to treatment. It concluded by finding that those with compensated cirrhosis were experiencing high cure rates when treated and that “Genotype 1a infection and male gender may be significant negative predictors of response to DAA in cirrhotic populations.” (Amitkumar Patel, et al.) Further investigation is required.

Additional information about the abstracts listed above or other abstracts that were part of Digestive Disease Week 2016 can be found in the Digestive Disease Week 2016’s online planner (click the abstracts tab and then the hepatitis C abstract category).